Literature DB >> 10022130

Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21.

A Suzuki1, Y Tsutomi, M Miura, K Akahane.   

Abstract

The death mediator caspase acts as the dominant regulator during cell death induction. The CPP32 subfamily, including caspase 3 (CPP32/Yama/Apopain), is essential for the cell death signaling. We recently reported that activation of caspase 3 is regulated by complex formation with p21 or ILP. In the present study, we investigated the binding domain with p21 and ILP to further characterize the caspase 3 inactivation machinery. Our results show that caspase 3 contains p21 binding domain in the N-terminus and ILP binding domain in the active site. Further, the caspase 3 binding domain in p21 was independent of the Cdk- or PCNA-binding domain. We also found caspase 3 protection by p21 from the p3-site cleavage serineproteinase contributes to the suppression machinery. Here, we propose the caspase 3 inactivation system by p21 and ILP as new essential system in the regulation of cell death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022130     DOI: 10.1038/sj.onc.1202409

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death.

Authors:  A Suzuki; Y Tsutomi; N Yamamoto; T Shibutani; K Akahane
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity.

Authors:  SungHwan Cho; Senthilkumar Cinghu; Jae-Ran Yu; Woo-Yoon Park
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-10       Impact factor: 4.553

Review 3.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

4.  Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.

Authors:  Brett Langley; Melissa A D'Annibale; Kyungsun Suh; Issam Ayoub; Aaron Tolhurst; Birgül Bastan; Lichuan Yang; Brian Ko; Marc Fisher; Sunghee Cho; M Flint Beal; Rajiv R Ratan
Journal:  J Neurosci       Date:  2008-01-02       Impact factor: 6.167

5.  MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.

Authors:  S Donzelli; G Fontemaggi; F Fazi; S Di Agostino; F Padula; F Biagioni; P Muti; S Strano; G Blandino
Journal:  Cell Death Differ       Date:  2011-12-23       Impact factor: 15.828

6.  Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation.

Authors:  J J Tang; C Shen; Y J Lu
Journal:  Mol Cell Biochem       Date:  2006-08-15       Impact factor: 3.396

7.  H2AX is required for cell cycle arrest via the p53/p21 pathway.

Authors:  Michalis Fragkos; Jaana Jurvansuu; Peter Beard
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

8.  p21Cip restrains hippocampal neurogenesis and protects neuronal progenitors from apoptosis during acute systemic inflammation.

Authors:  Svetlana Zonis; Vladimir A Ljubimov; Michael Mahgerefteh; Robert N Pechnick; Kolja Wawrowsky; Vera Chesnokova
Journal:  Hippocampus       Date:  2013-09-18       Impact factor: 3.899

9.  Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor.

Authors:  Elliott Taranto; Jin R Xue; Eric F Morand; Michelle Leech
Journal:  J Inflamm (Lond)       Date:  2009-08-24       Impact factor: 4.981

Review 10.  Understanding the mechanisms of drug-associated interstitial lung disease.

Authors:  T Higenbottam; K Kuwano; B Nemery; Y Fujita
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.